Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.
about
Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease.The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease.Directed differentiation of postnatal hippocampal neural stem cells generates nuclear receptor related‑1 protein‑ and tyrosine hydroxylase‑expressing cellsNeurotrophic molecules in the treatment of neurodegenerative disease with focus on the retina: status and perspectives.Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson's disease subjects.Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment.Effect of selegiline on neural stem cells differentiation: a possible role for neurotrophic factors.Brain-derived neurotrophic factor stimulates proliferation and differentiation of neural stem cells, possibly by triggering the Wnt/β-catenin signaling pathway.Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function.Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches.Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
P2860
Q29994860-05842DFD-82FA-47FB-B110-E18F6CDD610FQ33896035-22154D9F-0939-4356-A076-C0B11EF608F9Q35179790-D0205FE0-962D-4DFC-89AF-83874168FF28Q37190943-677DDB1B-5F12-4858-9F0E-329684A87DFEQ38086746-200084F5-C28F-46DE-9C5D-B1513127607FQ38112214-C2F7519A-2456-40E9-961F-19027B573FE4Q38325601-D38A8774-5A4F-46D5-8511-AF27C21DC95FQ40007799-B14C3901-77AE-4069-805E-6A28E5D1E306Q40460924-926E180A-A7D4-448A-A123-B2089434DC07Q40683415-193A03AF-DFF3-498C-BA66-68DB2EC54FCDQ44195362-CB72DEF1-9830-4CFA-BA96-C25C3DE895FBQ45300839-F4871E12-4959-4C5E-9D09-CC37255CD6EFQ47137101-2F7DBA4D-84B3-4659-BB13-459BA9E1D546Q47668415-9DC0A059-5EFD-457A-9EF3-39FDDDFEFBAA
P2860
Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Regulation of brain-derived ne ...... insonian drug therapy in vivo.
@en
type
label
Regulation of brain-derived ne ...... insonian drug therapy in vivo.
@en
prefLabel
Regulation of brain-derived ne ...... insonian drug therapy in vivo.
@en
P2860
P50
P1476
Regulation of brain-derived ne ...... insonian drug therapy in vivo.
@en
P2093
Päivi Lindholm
Tobias Gyárfás
P2860
P2888
P304
P356
10.1007/S10571-009-9458-3
P577
2009-09-24T00:00:00Z
P6179
1019214989